Listen to Thomas Fife-Schaw and Nick Gabery Adams, former VP of Corporate Brand at Novo Nordisk, discuss how GLP-1 medications like Ozempic and Wegovy are changing the pharmaceutical landscape. From reshaping corporate reputation, to boosting investor confidence, discover how these drugs are rewriting the rules for pharma brands.